GlassScriptPhysician profile
Carl D Devemark
NPI 1275944399
$3,000.90
in general payments reported to CMS, 2019-2025
11 companies · $35.98 in 2025
The $35.98 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2021: $122 · 2022: $2,129 · 2023: $218 · 2024: $172 · 2025: $35.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,469.63 | 2022 | |
| Integra Lifesciences Corporation | $509.88 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Intuitive Surgical, INC. | $300.98 | 2019-2022 | |
| Medical Device Business Services, INC. | $250.73 | 2021-2024 | Enseal |
| Atricure, INC. | $122.00 | 2022-2023 | |
| Depuy Synthes Sales INC. | $120.31 | 2022 | |
| Tei Biosciences INC | $115.87 | 2019 | |
| Tela Bio, INC. | $35.98 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Avanos Medical | $31.93 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $29.85 | 2024 | |
| Kls-Martin L.P. | $13.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Devemark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.